Allergan PLC. (AGN) is Baupost Group LLC MA’s 6th Largest Position
Baupost Group LLC MA reduced its position in shares of Allergan PLC. (NYSE:AGN) by 29.1% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 2,432,603 shares of the company’s stock after selling 1,000,000 shares during the period. Allergan PLC. comprises 6.8% of Baupost Group LLC MA’s holdings, making the stock its 6th largest position. Baupost Group LLC MA’s holdings in Allergan PLC. were worth $581,198,000 at the end of the most recent reporting period.
Other hedge funds have also bought and sold shares of the company. Pacific Center for Financial Services raised its position in Allergan PLC. by 805.1% in the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after buying an additional 475 shares in the last quarter. Stonebridge Capital Advisors LLC raised its position in Allergan PLC. by 3.7% in the first quarter. Stonebridge Capital Advisors LLC now owns 11,258 shares of the company’s stock worth $2,690,000 after buying an additional 398 shares in the last quarter. Ibex Wealth Advisors raised its position in Allergan PLC. by 4.7% in the first quarter. Ibex Wealth Advisors now owns 2,630 shares of the company’s stock worth $625,000 after buying an additional 118 shares in the last quarter. Steadfast Capital Management LP purchased a new position in Allergan PLC. during the first quarter worth approximately $29,311,000. Finally, Teachers Retirement System of The State of Kentucky raised its position in Allergan PLC. by 23.1% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 365,853 shares of the company’s stock worth $87,410,000 after buying an additional 68,763 shares in the last quarter. Hedge funds and other institutional investors own 84.77% of the company’s stock.
Shares of Allergan PLC. (NYSE:AGN) traded up 0.31% during midday trading on Friday, reaching $232.92. 843,379 shares of the company’s stock traded hands. The stock has a market cap of $78.07 billion, a price-to-earnings ratio of 7.10 and a beta of 1.16. The stock has a 50 day moving average of $246.34 and a 200-day moving average of $238.00. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same period last year, the firm posted $3.35 earnings per share. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, equities research analysts expect that Allergan PLC. will post $16.27 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.
COPYRIGHT VIOLATION NOTICE: “Allergan PLC. (AGN) is Baupost Group LLC MA’s 6th Largest Position” was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/11/allergan-plc-agn-is-baupost-group-llc-mas-6th-largest-position.html.
A number of equities analysts have recently commented on the stock. UBS AG reissued a “buy” rating and issued a $275.00 price target on shares of Allergan PLC. in a research report on Monday, May 15th. Vetr raised shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price target on the stock in a research report on Monday, June 26th. Royal Bank Of Canada set a $284.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a research report on Monday, June 12th. BidaskClub raised shares of Allergan PLC. from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Finally, Mizuho reissued a “buy” rating and issued a $267.00 price target on shares of Allergan PLC. in a research report on Wednesday, August 2nd. Eight equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $274.49.
In other news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.36% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.